Canagliflozin Increases Postprandial Total Glucagon-Like Peptide 1 Levels in the Absence of α-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A Single-Arm, Non-randomized, Open-Label Study

INTRODUCTION: To investigate canagliflozin-induced changes in postprandial total glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) levels in patients with type 2 diabetes mellitus (T2DM). METHODS: Forty-five patients with T2DM who had inadequate glycemic control...

Descripción completa

Detalles Bibliográficos
Autores principales: Osonoi, Takeshi, Tamasawa, Atsuko, Osonoi, Yusuke, Ofuchi, Kensuke, Katoh, Makoto, Saito, Miyoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848431/
https://www.ncbi.nlm.nih.gov/pubmed/31506889
http://dx.doi.org/10.1007/s13300-019-00689-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848431/
https://www.ncbi.nlm.nih.gov/pubmed/31506889
http://dx.doi.org/10.1007/s13300-019-00689-w

Ejemplares similares